Evaluation of CXCL8, CXCL10, CXCL11, CXCL12 and CXCL13 in serum and cerebrospinal fluid of patients with neuroborreliosis.
OBJECTIVE
Knowledge of the role of chemokines in the inflammation during neuroborreliosis (NB) is limited. We evaluated the pre- and post-treatment concentration of CXCL8, CXCL10, CXCL11, CXCL12, and CXCL13 in serum (s) and cerebrospinal fluid (csf) in patients with NB.


RESULTS
There was a statistically significant increase in pre-treatment s CXCL8, CXCL10, CXCL11, CXCL12, CXCL13 and csf CXCL8, CXCL11, CXCL12, CXCL13 in patients with early form of NB. CXCL8, CXCL11, CXCL12 and CXCL13 increase was the highest in csf. After treatment, a significant decrease in csf chemokine levels (except CXCL10) and s levels (except CXCL11) was observed.


CONCLUSIONS
CXCL8, CXCL10, CXCL11, CXCL12, CXCL13 are involved in the pathomechanism of NB but their role is different in s and csf. CXCL13 seems to be a good biomarker for NB. In early NB, it may facilitate the diagnosis and monitoring of therapy. However tick-borne encephalitis needs to be excluded as it also increases chemokine concentration. Decrease in all examined chemokines in s and csf after treatment suggests that chemokines may be useful in monitoring response to NB therapy.
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Żurawia 14, 15-540 Bialystok, Poland. Electronic address: annamoniuszko@op.pl.
Anna
A
Moniuszko
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Żurawia 14, 15-540 Bialystok, Poland.
Piotr
P
Czupryna
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Żurawia 14, 15-540 Bialystok, Poland.
Sławomir
S
Pancewicz
Department of Allergy, Cambridge University Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom.
Krzysztof
K
Rutkowski
Warsaw University of Life Sciences, Faculty of Applied Informatics and Mathematics, Nowourynowska 159, Warsaw 02-776, Poland.
Olga
O
Zajkowska
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Żurawia 14, 15-540 Bialystok, Poland.
Renata
R
Swierzbińska
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Żurawia 14, 15-540 Bialystok, Poland.
Sambor
S
Grygorczuk
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Żurawia 14, 15-540 Bialystok, Poland.
Maciej
M
Kondrusik
Department of Observation and Infectious Diseases (with a Subdivision of Pediatric Observation and Infectious Diseases), District General Hospital, Piłsudskiego 11, 18-400 Łomża, Poland.
Piotr
P
Owłasiuk
Department of Infectious Diseases and Neuroinfections, Medical University of Bialystok, Żurawia 14, 15-540 Bialystok, Poland.
Joanna
J
Zajkowska
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D054357:Chemokine CXCL10; D054371:Chemokine CXCL11; D054377:Chemokine CXCL12; D054382:Chemokine CXCL13; D019743:Chemokines, CXC / Q000097:blood* / Q000134:cerebrospinal fluid*; D005260:Female; D006801:Humans; D016209:Interleukin-8; D020852:Lyme Neuroborreliosis / Q000097:blood* / Q000134:cerebrospinal fluid*; D008297:Male; D008875:Middle Aged; D012372:ROC Curve; D012016:Reference Values
D054357:Chemokine CXCL10; D054371:Chemokine CXCL11; D054377:Chemokine CXCL12; D054382:Chemokine CXCL13; D019743:Chemokines, CXC; D016209:Interleukin-8
CXCL10; CXCL11; CXCL12; CXCL13; CXCL8; Neuroborreliosis